Vanadium Compounds for Normoglycemia in Critically Ill Patients

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Critically ill patients experiencing acute stress often develop hyperglycemia, which is associated with high mortality and morbidity, and current intensive insulin therapy methods are cumbersome, risky, and not always effective in maintaining normoglycemia, while existing treatments for renal ischemia-reperfusion and cardio-renal disorders are inadequate.

Innovation Solution

Administration of a pharmaceutical composition comprising physiologically acceptable organic and/or inorganic vanadium compounds or complexes, potentially combined with magnesium, fish oil, potassium, copper, selenium, vitamin D, vitamin E, chromium, or their mixtures, to maintain normoglycemia, prevent or limit renal ischemia-reperfusion, and treat cardio-renal disorders in critically ill patients.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If intensive insulin therapy is used to maintain normoglycemia, then blood glucose control is improved, but the complexity of monitoring and administration increases significantly

Engineering Contradiction:

Improveblood glucose controlVSAvoidmonitoring and administration complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces vanadium compounds as an intermediary substance that mimics insulin's metabolic effects without requiring the complex feedback control system. Vanadium acts as a mediator that directly enhances glucose uptake and utilization in cells, bypassing the need for continuous blood glucose monitoring and insulin dose adjustment that characterizes intensive insulin therapy

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the therapeutic parameter from exogenous insulin administration to vanadium compound administration. This parameter change fundamentally alters the treatment approach by using a substance that activates insulin signaling pathways and enhances glucose metabolism through different biochemical mechanisms, thereby simplifying the monitoring requirements while maintaining effective glucose control

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If frequent blood sampling is performed for monitoring, then measurement precision of blood sugar levels is improved, but loss of time and increased operational burden worsen

Engineering Contradiction:

Improveblood sugar level measurementVSAvoidnurse or technician time

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

Vanadium compounds serve as a pharmacological intermediary that produces sustained metabolic effects, allowing for less frequent monitoring intervals while still maintaining therapeutic benefit. The compound's mechanism of action and prolonged effect duration reduce the urgency for continuous monitoring that would otherwise be required with rapid-acting insulin regimens

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If intensive insulin therapy is administered, then normoglycemia is maintained, but the risk of hypoglycemia increases

Engineering Contradiction:

Improvenormoglycemia maintenanceVSAvoidhypoglycemia risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the pharmacological parameter from insulin (which directly lowers blood glucose) to vanadium compounds (which enhance cellular glucose utilization). This parameter change shifts the mechanism from glucose removal to metabolic enhancement, thereby maintaining normoglycemia through a different pathway that carries lower hypoglycemia risk

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the potential harm of hypoglycemia into benefit by using vanadium compounds that enhance glucose metabolism without causing rapid glucose drops. The compound's mechanism of improving insulin sensitivity and glucose uptake occurs through gradual metabolic adaptation rather than acute glucose lowering, thereby eliminating the hypoglycemia risk while maintaining therapeutic efficacy

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

4Ease of operation

If vanadium compounds are used for glucose control, then operational simplicity is improved, but knowledge of the mechanism of action deteriorates

Engineering Contradiction:

Improveadministration simplicityVSAvoidmechanism understanding

Core Design Contradiction:

Ease of operationVSLoss of information

Solution Approach 1:

Vanadium compounds function as a well-characterized intermediary with established mechanisms of action including activation of insulin receptor tyrosine kinase, enhancement of insulin signaling pathways, and stimulation of glucose transporter translocation. The mechanism is sufficiently understood to guide clinical use while maintaining operational simplicity

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20220040195A1Use of vanadium compounds for maintaining normaglycemia in a mammal

Publication Date: 2022.02.10 CFM PHARM HLDG BV

AI summary

The present invention relates to a method for maintaining normoglycemia in a mammal in need thereof, preferably a critically ill patient suffering from acute stress, and to a method for preventing or limiting renal ischemia-reperfusion (I/R) in a mammal, preferably in a critically ill patient suffering from acute stress.